The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study

Table 3 Association between fenofibrate use and the RNFL thickness of the right eye in patients with type 2 diabetes

Risk factors	B	S.E.	Sig.	95%CI for OR
Risk factors	B	S.E.	Sig.	upper	lower
Fenofibrate	3.225	1.605	*0.042	0.027	6.424
BMI	−3.475	1.611	*0.034	−6.678	−0.271
ACR	−0.650	0.281	*0.024	−1.210	−0.090
TC	−5.584	−0.269	0.538	−23.58	12.41
TG	−0.779	2.745	0.777	−6.248	4.689
HDL	9.329	13.320	0.486	17.211	35.869
LDL	6.834	10.310	0.510	13.710	27.378
HbA1c	1.382	1.703	0.420	−2.012	4.776
Diabetic duration	−0.337	0.484	0.488	−1.300	0.627
AL	−1.318	0.720	0.061	0.809	15.013
IOP	−0.547	0.550	0.310	0.126	1.573

BMI body mass index, DR diabetic retinopathy, HbA1c glycated hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, TC Total cholesterol, TG Triglyceride, ACR urinary albumin-to-creatinine ratio, RNFL retinal nerve fiber layer. S.E.standard error. Sig. significant. CI Confidence Interval, OR Odds Ratios. The multiple liner regression models were adjusted by age, gender, diabetic duration. * p < 0.05. A p value < 0.05 was defined as statistically significant

ISSN: 1471-2415